One example is the ongoing study conducted by the Hoosier Oncology Group that assesses PARP inhibition in patients with triple negative breast cancer or ER/PR+, HER2 negative disease with known BRCA1/2 mutations (NCT01074970) who had Miller-Payne response in the breast of 0–25 or RCB classification of II or III following neoadjuvant chemotherapy. The gene discussed is ESR1; the disease is triple-negative breast carcinoma.